| 1 | Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All? | 1.7 | 0 | Citations (PDF) |
| 2 | Sarcoma: Last Year’s Practice Changing Papers | 1.7 | 0 | Citations (PDF) |
| 3 | Is motherhood still possible after pelvic carbon ion radiotherapy? A promising combined fertility-preservation approach | 1.5 | 2 | Citations (PDF) |
| 4 | Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG) | 17.1 | 12 | Citations (PDF) |
| 5 | Initial local resection versus early referral for spermatic cord sarcoma: Any impact on treatment timelines and oncological outcomes? | 0.9 | 1 | Citations (PDF) |
| 6 | Reply to B. Schulte et al | 17.1 | 0 | Citations (PDF) |
| 7 | Outcomes of chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in nonresectable locally recurrent rectal cancer | 1.5 | 0 | Citations (PDF) |
| 8 | Survival after resection of malignant peripheral nerve sheath tumors: Introducing and validating a novel type-specific prognostic model | 0.7 | 0 | Citations (PDF) |
| 9 | Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) | 0.4 | 2 | Citations (PDF) |
| 10 | Progress in histology specific treatments in soft tissue sarcoma | 2.6 | 1 | Citations (PDF) |
| 11 | Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava | 1.7 | 1 | Citations (PDF) |
| 12 | Histology-Tailored Approach to Soft Tissue Sarcoma | 1.7 | 2 | Citations (PDF) |
| 13 | Preoperative nutritional support to tackle morbidity in multivisceral resection for retroperitoneal sarcoma. Early outcomes from a novel nutritional prehabilitation program in a prospective cohort | 0.9 | 1 | Citations (PDF) |
| 14 | Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group | 5.6 | 0 | Citations (PDF) |
| 15 | GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression | 6.4 | 0 | Citations (PDF) |
| 16 | How to treat liposarcomas located in retroperitoneum | 0.9 | 6 | Citations (PDF) |
| 17 | Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas | 0.9 | 16 | Citations (PDF) |
| 18 | <scp>CINSARC</scp> in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <scp>ISG‐STS</scp> 1001 study | 2.8 | 17 | Citations (PDF) |
| 19 | Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators | 4.0 | 12 | Citations (PDF) |
| 20 | Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study | 6.4 | 18 | Citations (PDF) |
| 21 | Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer | 3.3 | 45 | Citations (PDF) |
| 22 | Long term outcome of complex surgical resection and reconstruction for rare thoracic cancers | 1.5 | 2 | Citations (PDF) |
| 23 | NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours | 1.7 | 1 | Citations (PDF) |
| 24 | Staging Systems and Nomograms for Soft Tissue Sarcoma | 3.2 | 12 | Citations (PDF) |
| 25 | Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft | 2.7 | 7 | Citations (PDF) |
| 26 | Data Dissemination of the Role of Neoadjuvant Radiation in Retroperitoneal Sarcoma: A CTOS and CSSO Survey | 3.2 | 0 | Citations (PDF) |
| 27 | Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study | 3.3 | 4 | Citations (PDF) |
| 28 | A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2) | 1.7 | 11 | Citations (PDF) |
| 29 | Desmoid tumours (extra-abdominal), a surgeon’s nightmare | 3.8 | 1 | Citations (PDF) |
| 30 | Corrigenda | 3.8 | 0 | Citations (PDF) |
| 31 | Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study | 3.3 | 6 | Citations (PDF) |
| 32 | Postnephrectomy outcomes following <i>en bloc</i> resection of primary retroperitoneal sarcoma: multicentre study | 0.4 | 5 | Citations (PDF) |
| 33 | Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial | 4.4 | 66 | Citations (PDF) |
| 34 | Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts | 0.9 | 16 | Citations (PDF) |
| 35 | Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study | 6.4 | 25 | Citations (PDF) |
| 36 | SELNET clinical practice guidelines for soft tissue sarcoma and GIST | 10.1 | 50 | Citations (PDF) |
| 37 | Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution | 1.7 | 6 | Citations (PDF) |
| 38 | ASO Author Reflections: Outcome Improvement Over Time in Extremity and Trunk Wall Soft Tissue Sarcomas: To Whom the Merit? | 1.7 | 1 | Citations (PDF) |
| 39 | Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort | 0.9 | 14 | Citations (PDF) |
| 40 | So Now What? Unanswered Questions Regarding Retroperitoneal Sarcomas, Hospital Volume, Multidisciplinary Expertise, and Outcomes | 1.7 | 1 | Citations (PDF) |
| 41 | Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma | 1.7 | 5 | Citations (PDF) |
| 42 | A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis | 6.4 | 34 | Citations (PDF) |
| 43 | Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients | 1.7 | 24 | Citations (PDF) |
| 44 | Residual Adrenal Function After Multivisceral Resection With Adrenalectomy in Adult Patients | 9.8 | 5 | Citations (PDF) |
| 45 | Risk of misclassification during diagnosis of malnutrition in retroperitoneal sarcoma patients | 0.8 | 4 | Citations (PDF) |
| 46 | Overall survival in abdominal wall sarcoma treated with curative intent surgery: A retrospective study from two European referral centres | 1.7 | 1 | Citations (PDF) |
| 47 | Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward | 4.0 | 12 | Citations (PDF) |
| 48 | The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma | 1.7 | 6 | Citations (PDF) |
| 49 | Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor | 2.6 | 9 | Citations (PDF) |
| 50 | SELNET clinical practice guidelines for bone sarcoma | 5.3 | 21 | Citations (PDF) |
| 51 | Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States | 0.3 | 12 | Citations (PDF) |
| 52 | Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092‐22092 STRASS trial | 4.4 | 22 | Citations (PDF) |
| 53 | First‐line chemotherapy in advanced intra‐abdominal well‐differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis | 4.4 | 3 | Citations (PDF) |
| 54 | WHO Pathology | 1.9 | 9 | Citations (PDF) |
| 55 | Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma | 4.0 | 2 | Citations (PDF) |
| 56 | Desmoid Tumors 2022, , 619-627 | | 2 | Citations (PDF) |
| 57 | Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study | 3.3 | 9 | Citations (PDF) |
| 58 | Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group | 1.7 | 22 | Citations (PDF) |
| 59 | First and further-line multidisciplinary treatment of retroperitoneal sarcomas | 2.3 | 2 | Citations (PDF) |
| 60 | Traditional risk scores do not properly predict perioperative morbidity and mortality for retroperitoneal sarcoma resection | 1.7 | 1 | Citations (PDF) |
| 61 | Contemporary role of amputation for patients with extremity soft tissue sarcoma | 0.9 | 3 | Citations (PDF) |
| 62 | Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID‐19 pandemic: A guide for surgical oncologists | 1.7 | 7 | Citations (PDF) |
| 63 | Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy? | 1.9 | 17 | Citations (PDF) |
| 64 | Defining the role of neoadjuvant systemic therapy in high‐risk retroperitoneal sarcoma: A multi‐institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group | 4.4 | 35 | Citations (PDF) |
| 65 | The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only | 4.9 | 31 | Citations (PDF) |
| 66 | ASO Author Reflections: Reexcision after Macroscopically Complete Unplanned Excision in Extremity and Trunk Wall Soft Tissue Sarcoma: Is Less More? | 1.7 | 1 | Citations (PDF) |
| 67 | Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect? | 1.7 | 19 | Citations (PDF) |
| 68 | Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation | 11.5 | 15 | Citations (PDF) |
| 69 | Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group | 1.7 | 15 | Citations (PDF) |
| 70 | Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin | 4.0 | 16 | Citations (PDF) |
| 71 | Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program | 2.3 | 15 | Citations (PDF) |
| 72 | Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) | 1.7 | 19 | Citations (PDF) |
| 73 | Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities | 4.4 | 129 | Citations (PDF) |
| 74 | Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group | 1.7 | 145 | Citations (PDF) |
| 75 | ASO Author Reflections: Selecting Patients for Recurrent Retroperitoneal Sarcoma Surgery: The Challenging Trade-Off Between Oncologic Outcome and Morbidity | 1.7 | 1 | Citations (PDF) |
| 76 | Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid‐type fibromatosis | 2.8 | 5 | Citations (PDF) |
| 77 | Management of serious complications in intra‐abdominal desmoid‐type fibromatosis | 1.9 | 7 | Citations (PDF) |
| 78 | Dedifferentiation within well‐differentiated liposarcoma of the extremity or trunk: Implications for clinical management | 1.7 | 6 | Citations (PDF) |
| 79 | Oncological outcomes after major vascular resections for primary retroperitoneal liposarcoma | 0.9 | 16 | Citations (PDF) |
| 80 | Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study | 0.9 | 5 | Citations (PDF) |
| 81 | Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study | 0.9 | 37 | Citations (PDF) |
| 82 | Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial | 1.7 | 4 | Citations (PDF) |
| 83 | Major vascular resection in retroperitoneal sarcoma surgery | 1.9 | 16 | Citations (PDF) |
| 84 | Recurrent neck myxofibrosarcoma: a case report | 0.9 | 1 | Citations (PDF) |
| 85 | Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms | 3.3 | 15 | Citations (PDF) |
| 86 | Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG) | 1.7 | 27 | Citations (PDF) |
| 87 | Primary mesenteric sarcomas: Collaborative experience from the Trans‐Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) | 1.7 | 3 | Citations (PDF) |
| 88 | Gastrointestinal Stromal Tumors (GISTs) | 0.0 | 0 | Citations (PDF) |
| 89 | Volume-Outcome Relationship in Surgery of Soft Tissue Sarcomas | 0.0 | 0 | Citations (PDF) |
| 90 | Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models | 4.0 | 17 | Citations (PDF) |
| 91 | Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic | 3.6 | 6 | Citations (PDF) |
| 92 | Desmoid tumors: To treat or not to treat, That is the question | 4.4 | 42 | Citations (PDF) |
| 93 | Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa’ italiana di Ginecologia E Ostetricia) | 3.3 | 26 | Citations (PDF) |
| 94 | Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management | 4.0 | 33 | Citations (PDF) |
| 95 | Head and neck adult-type soft tissues sarcomas: survival analysis and comparison between the last two editions of the TNM staging system | 1.7 | 3 | Citations (PDF) |
| 96 | The Landmark Series: Multimodality Treatment of Extremity Sarcoma | 1.7 | 9 | Citations (PDF) |
| 97 | Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG | 4.4 | 22 | Citations (PDF) |
| 98 | Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals | 4.4 | 0 | Citations (PDF) |
| 99 | Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial | 21.9 | 319 | Citations (PDF) |
| 100 | ASO Author Reflections: Moving the Needle in Extremity and Trunk Soft Tissue Sarcoma | 1.7 | 1 | Citations (PDF) |
| 101 | Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups | 17.1 | 170 | Citations (PDF) |
| 102 | Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma | 1.7 | 11 | Citations (PDF) |
| 103 | Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors | 2.9 | 8 | Citations (PDF) |
| 104 | Defining Which Patients Are at High Risk for Recurrence of Soft Tissue Sarcoma | 4.3 | 13 | Citations (PDF) |
| 105 | Liver resection for sarcoma metastases: A systematic review and experience from two European centres | 0.9 | 10 | Citations (PDF) |
| 106 | Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis | 5.6 | 13 | Citations (PDF) |
| 107 | Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib | 9.8 | 37 | Citations (PDF) |
| 108 | Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group | 4.4 | 104 | Citations (PDF) |
| 109 | Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors | 6.4 | 20 | Citations (PDF) |
| 110 | Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas | 13.6 | 33 | Citations (PDF) |
| 111 | A sommelier to guide wine selection and a specialist to manage the sarcoma patient: Barriers to referral and definition of a sarcoma specialist | 1.7 | 4 | Citations (PDF) |
| 112 | The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group | 0.9 | 21 | Citations (PDF) |
| 113 | Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet | 4.4 | 49 | Citations (PDF) |
| 114 | Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine | 169.1 | 346 | Citations (PDF) |
| 115 | Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution | 1.7 | 16 | Citations (PDF) |
| 116 | Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group | 1.7 | 25 | Citations (PDF) |
| 117 | A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery | 1.7 | 15 | Citations (PDF) |
| 118 | Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years | 1.7 | 40 | Citations (PDF) |
| 119 | The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients | 3.3 | 308 | Citations (PDF) |
| 120 | ASO Author Reflections: Understanding the Impact of Primary Retroperitoneal Sarcoma Resection on Patient Well-being: One Step Forward in Learning How Caring for Patients is as Important as Curing Their Cancers | 1.7 | 1 | Citations (PDF) |
| 121 | Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis | 1.7 | 10 | Citations (PDF) |
| 122 | Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin | 5.7 | 11 | Citations (PDF) |
| 123 | Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis | 1.7 | 10 | Citations (PDF) |
| 124 | NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial | 21.9 | 343 | Citations (PDF) |
| 125 | Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft | 4.0 | 23 | Citations (PDF) |
| 126 | ASO Author Reflections: A Breach in the Border—Retroperitoneal Sarcoma with an Intraperitoneal Component | 1.7 | 0 | Citations (PDF) |
| 127 | The evolving role of patient advocates in rare cancers: opportunities and challenges | 1.6 | 2 | Citations (PDF) |
| 128 | Treatment of Desmoid Tumors in 2019 | 13.6 | 38 | Citations (PDF) |
| 129 | The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial | 3.3 | 150 | Citations (PDF) |
| 130 | Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas) | 6.4 | 84 | Citations (PDF) |
| 131 | Personalizing surgical margins in retroperitoneal sarcomas: an update | 2.6 | 49 | Citations (PDF) |
| 132 | Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments | 2.3 | 16 | Citations (PDF) |
| 133 | Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups | 8.8 | 54 | Citations (PDF) |
| 134 | NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas | 5.2 | 28 | Citations (PDF) |
| 135 | Outcome of iliocaval resection and reconstruction for retroperitoneal sarcoma | 1.8 | 24 | Citations (PDF) |
| 136 | Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG | 6.4 | 83 | Citations (PDF) |
| 137 | Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study | 3.6 | 27 | Citations (PDF) |
| 138 | Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors | 8.8 | 52 | Citations (PDF) |
| 139 | New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration | 2.3 | 57 | Citations (PDF) |
| 140 | Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas | 6.4 | 17 | Citations (PDF) |
| 141 | Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study | 3.3 | 32 | Citations (PDF) |
| 142 | Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group | 4.4 | 75 | Citations (PDF) |
| 143 | Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy | 1.7 | 12 | Citations (PDF) |
| 144 | Treatment challenges in and outside a network setting: Soft tissue sarcomas | 0.9 | 29 | Citations (PDF) |
| 145 | Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study | 1.7 | 23 | Citations (PDF) |
| 146 | Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization? | 1.4 | 6 | Citations (PDF) |
| 147 | Towards a Global Collaboration: the Trans-Atlantic Retroperitoneal Sarcoma Working Group | 0.0 | 0 | Citations (PDF) |
| 148 | History of Surgery in Retroperitoneal Sarcomas | 0.0 | 1 | Citations (PDF) |
| 149 | Predicting the Risk of Recurrence in Retroperitoneal Sarcoma | 0.0 | 0 | Citations (PDF) |
| 150 | High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial | 3.3 | 56 | Citations (PDF) |
| 151 | Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard? | 1.7 | 25 | Citations (PDF) |
| 152 | Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma | 13.6 | 247 | Citations (PDF) |
| 153 | Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients | 2.7 | 2 | Citations (PDF) |
| 154 | Prospective assessment of the predictive value of the <i>BRCA1</i> gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial | 2.8 | 7 | Citations (PDF) |
| 155 | Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial | 0.9 | 86 | Citations (PDF) |
| 156 | Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma | 13.6 | 63 | Citations (PDF) |
| 157 | Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials | 3.6 | 25 | Citations (PDF) |
| 158 | Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma | 0.9 | 30 | Citations (PDF) |
| 159 | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) | 4.5 | 34 | Citations (PDF) |
| 160 | Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma | 0.9 | 50 | Citations (PDF) |
| 161 | Synovial sarcomas of the upper aero-digestive tract: is there a role for conservative surgery? | 1.8 | 3 | Citations (PDF) |
| 162 | Working to improve the management of sarcoma patients across Europe: a policy checklist | 3.0 | 20 | Citations (PDF) |
| 163 | Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study | 3.3 | 6 | Citations (PDF) |
| 164 | European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy | 1.6 | 29 | Citations (PDF) |
| 165 | Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database | 1.9 | 11 | Citations (PDF) |
| 166 | Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma | 4.9 | 155 | Citations (PDF) |
| 167 | Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high‐grade lesions | 3.7 | 110 | Citations (PDF) |
| 168 | Retroperitoneal sarcomas: Big tumors that involve more than just “Getting it Out” | 1.7 | 2 | Citations (PDF) |
| 169 | Soft Tissue Tumors of the Groin and Inguinal Region 2018, , 123-157 | | 1 | Citations (PDF) |
| 170 | Historical perspectives and future directions in the surgical management of retroperitoneal sarcoma | 1.7 | 21 | Citations (PDF) |
| 171 | Perioperative Management of Extremity Soft Tissue Sarcomas | 17.1 | 37 | Citations (PDF) |
| 172 | Consistent Margin-Status Reporting in Soft Tissue Sarcoma Is Essential to Establish Risk-Adapted Strategies Integrating Biology and Histotype in Perioperative Treatments | 17.1 | 5 | Citations (PDF) |
| 173 | ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma | 1.7 | 1 | Citations (PDF) |
| 174 | A call to action: Why sarcoma surgery needs to be centralized | 4.4 | 14 | Citations (PDF) |
| 175 | Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres | 3.3 | 63 | Citations (PDF) |
| 176 | Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature | 2.7 | 41 | Citations (PDF) |
| 177 | Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study | 4.4 | 45 | Citations (PDF) |
| 178 | Surgical resection as an adjuvant to tyrosine kinase inhibitors in metastatic GIST: Association or causation?/Are we any closer to an answer? | 0.9 | 1 | Citations (PDF) |
| 179 | Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should | 1.7 | 6 | Citations (PDF) |
| 180 | Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach | 2.7 | 12 | Citations (PDF) |
| 181 | Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma | 4.5 | 5 | Citations (PDF) |
| 182 | 2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma | 5.6 | 5 | Citations (PDF) |
| 183 | Towards the standard use of (neo)adjuvant chemotherapy in selected localised soft tissue sarcoma at high risk of relapse: are we finally getting there? | 3.3 | 2 | Citations (PDF) |
| 184 | The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk | 13.6 | 10 | Citations (PDF) |
| 185 | Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma | 1.2 | 14 | Citations (PDF) |
| 186 | Novel intra‐genic large deletions of<i>CTNNB1</i>gene identified in WT desmoid‐type fibromatosis | 3.5 | 17 | Citations (PDF) |
| 187 | Principles of Local Therapy of Soft Tissue Neoplasms 2018, , 55-65 | | 0 | Citations (PDF) |
| 188 | Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis | 1.7 | 13 | Citations (PDF) |
| 189 | Surrogate endpoints in advanced sarcoma trials: a meta-analysis | 1.7 | 8 | Citations (PDF) |
| 190 | Surgical management of retroperitoneal sarcoma and opportunities for global collaboration | 1.4 | 24 | Citations (PDF) |
| 191 | Staging, nomograms and other predictive tools in retroperitoneal soft tissue sarcoma | 1.4 | 17 | Citations (PDF) |
| 192 | Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome | 6.4 | 68 | Citations (PDF) |
| 193 | Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST | 2.9 | 52 | Citations (PDF) |
| 194 | Pharmacological therapies for Liposarcoma | 2.9 | 17 | Citations (PDF) |
| 195 | Post‐relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans‐Atlantic RPS Working Group | 4.4 | 114 | Citations (PDF) |
| 196 | Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis | 0.4 | 84 | Citations (PDF) |
| 197 | Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour | 3.3 | 25 | Citations (PDF) |
| 198 | Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients | 3.3 | 66 | Citations (PDF) |
| 199 | Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study | 1.9 | 35 | Citations (PDF) |
| 200 | Soft tissue sarcoma nomograms and their incorporation into practice | 4.4 | 113 | Citations (PDF) |
| 201 | Neoadjuvant treatment: a novel standard? | 2.3 | 10 | Citations (PDF) |
| 202 | Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial | 21.9 | 381 | Citations (PDF) |
| 203 | β‐Catenin in desmoid‐type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression | 4.2 | 27 | Citations (PDF) |
| 204 | Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis | 1.9 | 73 | Citations (PDF) |
| 205 | Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications | 3.8 | 105 | Citations (PDF) |
| 206 | <scp>HSPA</scp>8 as a novel fusion partner of <scp>NR</scp>4<scp>A</scp>3 in extraskeletal myxoid chondrosarcoma | 3.5 | 38 | Citations (PDF) |
| 207 | An Update on Non-extremity Soft Tissue Sarcomas | 1.6 | 6 | Citations (PDF) |
| 208 | Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions | 0.9 | 11 | Citations (PDF) |
| 209 | Surgery for recurrence in retroperitoneal leiomyosarcoma: Is it all about selection? | 1.7 | 2 | Citations (PDF) |
| 210 | Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma | 5.7 | 21 | Citations (PDF) |
| 211 | Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new | 7.4 | 60 | Citations (PDF) |
| 212 | Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis | 1.9 | 154 | Citations (PDF) |
| 213 | (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair | 3.3 | 39 | Citations (PDF) |
| 214 | Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment | 0.7 | 28 | Citations (PDF) |
| 215 | High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma | 1.5 | 6 | Citations (PDF) |
| 216 | Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting | 7.4 | 4 | Citations (PDF) |
| 217 | Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma | 2.0 | 22 | Citations (PDF) |
| 218 | Long-Term Results of Thoraco-Pleuro-Pneumonectomy (TPP) for Recurrent Thoracic Sarcomas | 1.7 | 2 | Citations (PDF) |
| 219 | Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue | 1.7 | 14 | Citations (PDF) |
| 220 | Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels | 17.1 | 153 | Citations (PDF) |
| 221 | Adjacent, Adherent, Invaded: A Spectrum of Biologic Aggressiveness Rather Than a Rationale for Selecting Organ Resection in Surgery of Primary Retroperitoneal Sarcomas | 1.7 | 14 | Citations (PDF) |
| 222 | Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs | 5.0 | 5 | Citations (PDF) |
| 223 | External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis | 1.7 | 98 | Citations (PDF) |
| 224 | Sarcoma nomograms: a light over the darkness | 1.6 | 8 | Citations (PDF) |
| 225 | Retroperitoneal Sarcoma Involving the Inferior Vena Cava 2017, , 61-74 | | 1 | Citations (PDF) |
| 226 | Local Ablative Therapies to Metastatic Soft Tissue Sarcoma | 5.1 | 17 | Citations (PDF) |
| 227 | Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS) | 4.9 | 416 | Citations (PDF) |
| 228 | Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference CentersSpine, 2016, 41, 1049-1057 | 2.4 | 72 | Citations (PDF) |
| 229 | External validation of a multi‐institutional retroperitoneal sarcoma nomogram | 4.4 | 85 | Citations (PDF) |
| 230 | Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis | 21.9 | 351 | Citations (PDF) |
| 231 | Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy | 1.6 | 13 | Citations (PDF) |
| 232 | The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma | 2.6 | 5 | Citations (PDF) |
| 233 | Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial–Mesenchymal Transition–like Process and 22q Loss | 2.9 | 25 | Citations (PDF) |
| 234 | Desmoid-Type Fibromatosis | 1.9 | 64 | Citations (PDF) |
| 235 | <i><scp>AKT</scp>1</i> and <i><scp>BRAF</scp></i> mutations in pediatric aggressive fibromatosis | 2.8 | 28 | Citations (PDF) |
| 236 | Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSG | 3.3 | 33 | Citations (PDF) |
| 237 | Cancer registries and randomised clinical trials in rare tumours: At the two extremes of daily clinical practice | 3.3 | 5 | Citations (PDF) |
| 238 | The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): “Red wine or white”? | 1.7 | 14 | Citations (PDF) |
| 239 | Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database | 1.7 | 57 | Citations (PDF) |
| 240 | Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group | 1.5 | 95 | Citations (PDF) |
| 241 | The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers | 1.8 | 2 | Citations (PDF) |
| 242 | Indications for surgery in advanced/metastatic GIST | 3.3 | 42 | Citations (PDF) |
| 243 | Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum | 2.1 | 40 | Citations (PDF) |
| 244 | Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC – STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging | 3.3 | 45 | Citations (PDF) |
| 245 | Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy | 0.6 | 14 | Citations (PDF) |
| 246 | Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions | 0.9 | 59 | Citations (PDF) |
| 247 | Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study | 0.9 | 91 | Citations (PDF) |
| 248 | Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity | 3.3 | 120 | Citations (PDF) |
| 249 | Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC–STBSG) recommendations for pathological examination and reporting | 3.3 | 111 | Citations (PDF) |
| 250 | Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP) | 6.4 | 75 | Citations (PDF) |
| 251 | Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors? | 1.7 | 4 | Citations (PDF) |
| 252 | Accreditation for centers of sarcoma surgery | 1.8 | 16 | Citations (PDF) |
| 253 | Abdominosacral resection for locally recurring rectal cancer | 1.5 | 4 | Citations (PDF) |
| 254 | Long-term morbidity after multivisceral resection for retroperitoneal sarcoma | 0.4 | 45 | Citations (PDF) |
| 255 | KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST | 3.9 | 62 | Citations (PDF) |
| 256 | Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma | 3.9 | 106 | Citations (PDF) |
| 257 | Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation | 5.0 | 70 | Citations (PDF) |
| 258 | Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas | 17.1 | 146 | Citations (PDF) |
| 259 | Personalizing surgical margins in retroperitoneal sarcomas | 2.6 | 35 | Citations (PDF) |
| 260 | Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients | 3.3 | 129 | Citations (PDF) |
| 261 | Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study | 3.3 | 139 | Citations (PDF) |
| 262 | The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma | 1.7 | 10 | Citations (PDF) |
| 263 | Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative | 3.3 | 190 | Citations (PDF) |
| 264 | Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): When abstention is better than care | 1.7 | 8 | Citations (PDF) |
| 265 | Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series | 1.7 | 1 | Citations (PDF) |
| 266 | Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide | 17.1 | 61 | Citations (PDF) |
| 267 | Imatinib in advanced chordoma: A retrospective case series analysis | 3.3 | 79 | Citations (PDF) |
| 268 | Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis | 3.3 | 59 | Citations (PDF) |
| 269 | Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors | 3.3 | 102 | Citations (PDF) |
| 270 | Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis | 0.4 | 32 | Citations (PDF) |
| 271 | Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy | 5.7 | 21 | Citations (PDF) |
| 272 | Surgical management of localized soft tissue tumors | 4.4 | 46 | Citations (PDF) |
| 273 | Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center | 0.9 | 34 | Citations (PDF) |
| 274 | Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials | 1.5 | 132 | Citations (PDF) |
| 275 | Emerging therapies for adult soft tissue sarcoma | 2.6 | 50 | Citations (PDF) |
| 276 | Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies | 0.9 | 12 | Citations (PDF) |
| 277 | High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma | 2.0 | 43 | Citations (PDF) |
| 278 | MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study | 1.7 | 27 | Citations (PDF) |
| 279 | Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group | 1.5 | 146 | Citations (PDF) |
| 280 | Activity of sunitinib in extraskeletal myxoid chondrosarcoma | 3.3 | 70 | Citations (PDF) |
| 281 | Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents | 2.5 | 17 | Citations (PDF) |
| 282 | Thoracopleuropneumonectomy with Riblike Reconstruction for Recurrent Thoracic Sarcomas | 1.7 | 11 | Citations (PDF) |
| 283 | Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour | 3.3 | 48 | Citations (PDF) |
| 284 | Prognostic Factors and Outcome of Spermatic Cord Sarcoma | 1.7 | 28 | Citations (PDF) |
| 285 | Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I–II study from the Italian Sarcoma Group | 3.3 | 79 | Citations (PDF) |
| 286 | Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – Analysis of prognostic factors (EORTC-STBSG collaborative study) | 0.9 | 132 | Citations (PDF) |
| 287 | Desmoid-Type Fibromatosis and Pregnancy | 4.9 | 96 | Citations (PDF) |
| 288 | Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection | 1.7 | 152 | Citations (PDF) |
| 289 | Identification of a gene expression driven progression pathway in myxoid liposarcoma | 1.7 | 16 | Citations (PDF) |
| 290 | Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib | 2.0 | 38 | Citations (PDF) |
| 291 | Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients | 2.0 | 86 | Citations (PDF) |
| 292 | Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult | 4.3 | 12 | Citations (PDF) |
| 293 | Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience | 1.7 | 193 | Citations (PDF) |
| 294 | Risk stratification models and mutational analysis: Keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour | 3.3 | 24 | Citations (PDF) |
| 295 | Localised thoracic sarcomas: Outcome improvement over time at a single institution | 3.3 | 14 | Citations (PDF) |
| 296 | Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought | 1.7 | 196 | Citations (PDF) |
| 297 | Treatment of Localized Sarcomas | 2.4 | 12 | Citations (PDF) |
| 298 | Quality of Local Treatment or Biology of the Tumor: Which are the Trump Cards for Loco-regional Control of Retroperitoneal Sarcoma? | 1.7 | 31 | Citations (PDF) |
| 299 | Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study | 2.0 | 32 | Citations (PDF) |
| 300 | In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas | 3.5 | 18 | Citations (PDF) |
| 301 | Response to chemotherapy of solitary fibrous tumour: A retrospective study | 3.3 | 67 | Citations (PDF) |
| 302 | Cytoreductive Surgery in Advanced GIST: Timing is Everything | 1.7 | 7 | Citations (PDF) |
| 303 | Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall | 1.5 | 68 | Citations (PDF) |
| 304 | Phase II study on lapatinib in advanced EGFR-positive chordoma | 1.5 | 121 | Citations (PDF) |
| 305 | Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors | 3.6 | 9 | Citations (PDF) |
| 306 | Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets | 17.1 | 278 | Citations (PDF) |
| 307 | CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence | 4.4 | 154 | Citations (PDF) |
| 308 | Mode of action of trabectedin in myxoid liposarcomas | 6.6 | 111 | Citations (PDF) |
| 309 | A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients | 1.5 | 43 | Citations (PDF) |
| 310 | Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas | 1.5 | 187 | Citations (PDF) |
| 311 | Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group | 17.1 | 145 | Citations (PDF) |
| 312 | Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma | 1.5 | 125 | Citations (PDF) |
| 313 | Phase II Study of Imatinib in Advanced Chordoma | 17.1 | 220 | Citations (PDF) |
| 314 | Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management | 2.6 | 7 | Citations (PDF) |
| 315 | Sunitinib malate in solitary fibrous tumor (SFT) | 1.5 | 129 | Citations (PDF) |
| 316 | High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors | 3.9 | 90 | Citations (PDF) |
| 317 | Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance | 0.9 | 22 | Citations (PDF) |
| 318 | Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study | 1.7 | 58 | Citations (PDF) |
| 319 | Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum | 2.6 | 18 | Citations (PDF) |
| 320 | Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC–STBSG | 1.7 | 208 | Citations (PDF) |
| 321 | Optimal Approach to Sporadic Desmoid Tumors: From Radical Surgery to Observation. Time for a Consensus? | 1.7 | 15 | Citations (PDF) |
| 322 | Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib | 2.0 | 26 | Citations (PDF) |
| 323 | Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST) | 4.3 | 17 | Citations (PDF) |
| 324 | Leiomyosarcoma and sarcoma with myogenic differentiation | 4.4 | 3 | Citations (PDF) |
| 325 | Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapy | 4.4 | 83 | Citations (PDF) |
| 326 | Receptor tyrosine kinase pathway analysis sheds light on similarities between clear‐cell sarcoma and metastatic melanoma | 3.5 | 22 | Citations (PDF) |
| 327 | Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib | 1.7 | 104 | Citations (PDF) |
| 328 | Prognostic determinants in epithelioid sarcoma | 3.3 | 45 | Citations (PDF) |
| 329 | Natural History of Imatinib-naive GISTs | 3.9 | 112 | Citations (PDF) |
| 330 | Surgery in Retroperitoneal Soft Tissue Sarcoma: A Call for a Consensus Between Europe and North America | 1.7 | 36 | Citations (PDF) |
| 331 | Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy | 6.5 | 9 | Citations (PDF) |
| 332 | High CD133 expression levels in gastrointestinal stromal tumors | 1.7 | 9 | Citations (PDF) |
| 333 | Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study | 4.5 | 18 | Citations (PDF) |
| 334 | Dermatofibrosarcoma protuberans‐derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib | 4.5 | 62 | Citations (PDF) |
| 335 | Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution | 1.5 | 40 | Citations (PDF) |
| 336 | Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect | 1.5 | 188 | Citations (PDF) |
| 337 | Surgical Technique, Morbidity, and Outcome of Primary Retroperitoneal Sarcoma Involving Inferior Vena Cava | 1.7 | 98 | Citations (PDF) |
| 338 | The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones | 1.7 | 30 | Citations (PDF) |
| 339 | Surgical Treatment 2011, , 107-112 | | 0 | Citations (PDF) |
| 340 | Aggressive fibromatosis in children and adolescents | 4.4 | 121 | Citations (PDF) |
| 341 | Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution | 4.9 | 263 | Citations (PDF) |
| 342 | Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control | 1.7 | 262 | Citations (PDF) |
| 343 | Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy? | 1.7 | 77 | Citations (PDF) |
| 344 | Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis | 3.0 | 31 | Citations (PDF) |
| 345 | The role of high‐dose imatinib in the management of patients with gastrointestinal stromal tumor | 4.4 | 24 | Citations (PDF) |
| 346 | Histology‐specific nomogram for primary retroperitoneal soft tissue sarcoma | 4.4 | 89 | Citations (PDF) |
| 347 | Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors | 6.4 | 26 | Citations (PDF) |
| 348 | Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response | 1.7 | 81 | Citations (PDF) |
| 349 | Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells | 0.6 | 241 | Citations (PDF) |
| 350 | Tumor response to sunitinib malate observed in clear-cell sarcoma | 1.5 | 35 | Citations (PDF) |
| 351 | Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? | 1.5 | 123 | Citations (PDF) |
| 352 | Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas | 0.9 | 79 | Citations (PDF) |
| 353 | Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution | 1.7 | 79 | Citations (PDF) |
| 354 | Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution | 1.7 | 201 | Citations (PDF) |
| 355 | ILP and RT: The Study That Will Never Be | 1.7 | 11 | Citations (PDF) |
| 356 | Hyperthermia as an adjunctive treatment for soft-tissue sarcoma | 2.6 | 25 | Citations (PDF) |
| 357 | Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size | 17.1 | 50 | Citations (PDF) |
| 358 | Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma | 17.1 | 46 | Citations (PDF) |
| 359 | Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series | 1.5 | 105 | Citations (PDF) |
| 360 | Response to imatinib plus sirolimus in advanced chordoma | 1.5 | 137 | Citations (PDF) |
| 361 | Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma | 6.4 | 124 | Citations (PDF) |
| 362 | Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors | 1.7 | 154 | Citations (PDF) |
| 363 | Activate and resist: L576P-KIT in GIST | 1.7 | 31 | Citations (PDF) |
| 364 | Gastrointestinal Stromal Tumors I: Pathology, Pathobiology, Primary Therapy, and Surgical Issues | 1.9 | 35 | Citations (PDF) |
| 365 | Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment | 1.7 | 318 | Citations (PDF) |
| 366 | Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS) | 3.3 | 29 | Citations (PDF) |
| 367 | Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST) | 0.9 | 146 | Citations (PDF) |
| 368 | PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor | 0.9 | 72 | Citations (PDF) |
| 369 | Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients | 17.1 | 406 | Citations (PDF) |
| 370 | Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management | 2.6 | 38 | Citations (PDF) |
| 371 | Desmoid-type fibromatosis: What works best? | 3.3 | 10 | Citations (PDF) |
| 372 | Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers | 1.7 | 152 | Citations (PDF) |
| 373 | The prognostic impact of dedifferentiation in retroperitoneal liposarcoma | 4.4 | 80 | Citations (PDF) |
| 374 | Is Autophagy Rather Than Apoptosis the Regression Driver in Imatinib-Treated Gastrointestinal Stromal Tumors? | 3.8 | 20 | Citations (PDF) |
| 375 | Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma | 0.9 | 17 | Citations (PDF) |
| 376 | Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 | 6.4 | 145 | Citations (PDF) |
| 377 | Combined modalities approach for localized adult extremity soft-tissue sarcoma | 2.6 | 9 | Citations (PDF) |
| 378 | c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors | 6.4 | 55 | Citations (PDF) |
| 379 | Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis | 6.4 | 75 | Citations (PDF) |
| 380 | Chordoma | 2.3 | 138 | Citations (PDF) |
| 381 | Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma | 3.3 | 40 | Citations (PDF) |
| 382 | Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study | 21.9 | 379 | Citations (PDF) |
| 383 | Myxoid/round cell and pleomorphic liposarcomas | 4.4 | 145 | Citations (PDF) |
| 384 | Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure | 1.7 | 71 | Citations (PDF) |
| 385 | Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution | 1.7 | 78 | Citations (PDF) |
| 386 | Soft-tissue sarcomas of the extremities in patients of pediatric age | 1.8 | 9 | Citations (PDF) |
| 387 | Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity | 1.7 | 137 | Citations (PDF) |
| 388 | Epithelioid sarcoma in children and adolescents | 4.4 | 96 | Citations (PDF) |
| 389 | Malignant peripheral nerve sheath tumors | 4.4 | 349 | Citations (PDF) |
| 390 | Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas | 6.4 | 128 | Citations (PDF) |
| 391 | Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression | 0.6 | 112 | Citations (PDF) |
| 392 | Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution | 1.7 | 60 | Citations (PDF) |
| 393 | Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system | 4.4 | 174 | Citations (PDF) |
| 394 | 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized forc-kit and platelet-derived growth factor receptor α gene alterations | 4.4 | 53 | Citations (PDF) |
| 395 | Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan | 17.1 | 123 | Citations (PDF) |
| 396 | Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate | 17.1 | 170 | Citations (PDF) |
| 397 | Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution | 17.1 | 235 | Citations (PDF) |
| 398 | Consensus meeting for the management of gastrointestinal stromal tumors
Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO | 1.5 | 586 | Citations (PDF) |
| 399 | Carney triad: case report and molecular analysis of gastric tumor | 2.4 | 59 | Citations (PDF) |
| 400 | Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial Sarcoma | 6.4 | 57 | Citations (PDF) |
| 401 | Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis | 4.4 | 100 | Citations (PDF) |
| 402 | Retroperitoneal soft tissue sarcomas | 4.4 | 164 | Citations (PDF) |
| 403 | Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution | 4.4 | 329 | Citations (PDF) |
| 404 | Imatinib mesylate in chordoma | 4.4 | 233 | Citations (PDF) |
| 405 | Sacro-coccygeal chordoma: Diagnosis and treatment review | 0.4 | 0 | Citations (PDF) |
| 406 | A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient | 1.0 | 339 | Citations (PDF) |
| 407 | Uterine Sarcoma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion: a Feasiblity Study | 1.7 | 14 | Citations (PDF) |
| 408 | Rhabdomyosarcoma in adults | 4.4 | 338 | Citations (PDF) |
| 409 | Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution | 1.7 | 184 | Citations (PDF) |
| 410 | Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution | 17.1 | 302 | Citations (PDF) |
| 411 | Evidence of Neural Differentiation in a Case of Post-therapy Primitive Neuroectodermal Tumor/Ewing Sarcoma of Bone | 3.9 | 25 | Citations (PDF) |
| 412 | Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei | 1.5 | 16 | Citations (PDF) |
| 413 | Lack of SYT-SSX Fusion Transcripts in Malignant Peripheral Nerve Sheath Tumors on RT-PCR Analysis of 34 Archival Cases | 3.5 | 35 | Citations (PDF) |
| 414 | Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis | 4.4 | 222 | Citations (PDF) |
| 415 | Hemangiopericytoma in pediatric ages | 4.4 | 48 | Citations (PDF) |
| 416 | Preoperative radiation therapy for patients with T2-T3 carcinoma of the middle-to-lower rectum | 4.4 | 40 | Citations (PDF) |
| 417 | Surgical treatment of locally recurrent rectal carcinoma | 1.8 | 62 | Citations (PDF) |
| 418 | First- and second-line systemic treatments for metastatic and locally advanced soft tissue sarcomas in adults | 2.4 | 1 | Citations (PDF) |
